The global pharma giant cut more than 400 jobs in the state last year, after investing at least $360 million in its local manufacturing operations.

Regenxbio filed a lawsuit in 2020 alleging that Elevidys infringed a gene-therapy patent that the company licenses from ...

Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. | Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. This ...

Biotech company Regenxbio and the University of Pennsylvania on Friday convinced a U.S. appeals court to revive their patent lawsuit against Sarepta Therapeutics over Sarepta's Duchenne muscular ...

Japan’s Chugai today announced that it launched Elevidys intravenous infusion (delandistrogene moxeparvovec), which received ...

Lasting gains in swallowing ability have been reported for four people with oculopharyngeal muscular dystrophy given gene therapy in a trial.

We expect investors to focus on pipeline updates when Keros Therapeutics KROS reports fourth-quarter results shortly. The Zacks Consensus Estimate for sales and loss per share is pegged at $6.50 ...

Shares in Sarepta reversed some of their recent declines after the FDA added a warning label to its Duchenne muscular dystrophy (DMD) gene therapy, ending a protracted period of uncertainty for the ...

An advisory panel to Japan's health minister decided Friday to allow public health insurance coverage for a gene therapy for muscular dystrophy beginning Feb. 20 and set the drug's official price at ...

In a statement, PTC's chief executive, Matthew Klein, said the company had decided to pull the filing for Translarna (ataluren) as a treatment for nonsense mutation DMD after the FDA said it was ...

The FDA’s refusal to review Moderna’s mRNA-based flu vaccine is part of a larger communications crisis unfolding at the agency over the past nine months that has also ensnarled Sarepta, Capricor, ...

The FDA has cleared the company's investigational new drug application seeking to begin the Phase I/II FUNCTION-DMD trial.